Contrasting Spectral AI (MDAI) & The Competition

Spectral AI (NASDAQ:MDAI) is one of 225 public companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare Spectral AI to related companies based on the strength of its institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and risk.

Profitability

This table compares Spectral AI and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-89.85%	N/A	-104.64%
Spectral AI Competitors	-578.37%	-140.27%	-25.88%

Earnings and Valuation

This table compares Spectral AI and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spectral AI	$22.53 million	-$20.85 million	-0.92
Spectral AI Competitors	$876.28 million	$48.15 million	4.46

Spectral AI’s competitors have higher revenue and earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and price targets for Spectral AI and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0	0	3	1	3.25
Spectral AI Competitors	1665	4407	8440	250	2.49

Spectral AI currently has a consensus target price of $4.50, indicating a potential upside of 265.85%. As a group, “Surgical & medical instruments” companies have a potential upside of 17.83%. Given Spectral AI’s stronger consensus rating and higher possible upside, research analysts plainly believe Spectral AI is more favorable than its competitors.

Risk and Volatility

Spectral AI has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Spectral AI’s competitors have a beta of 0.52, meaning that their average stock price is 48% less volatile than the S&P 500.

Institutional & Insider Ownership

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 47.6% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 56.7% of Spectral AI shares are owned by insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Spectral AI beats its competitors on 9 of the 13 factors compared.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.